Argenx Se (ARGX) Other Non-Current Liabilities (2016 - 2017)
Argenx Se's (ARGX) quarterly Other Non-Current Liabilities came in at $14.4 million in Q2 2017, up 9.14% quarter-over-quarter from $13.2 million in Q4 2016.
Powered by 
Analysis
Argenx Se (ARGX) Other Non-Current Liabilities (2016 - 2017) Analysis & Trends
Argenx Se (ARGX) has reported Other Non-Current Liabilities for 2 consecutive years, with $14.4 million the latest figure, recorded in Q2 2017.
- For the quarter ending Q2 2017, Other Non-Current Liabilities changed N/A year-over-year to $14.4 million; the trailing twelve-month figure through Jun 2017 stood at $14.4 million (changed N/A YoY), and the FY2016 full-year result was $13.5 million, changed N/A from the prior year.
- Other Non-Current Liabilities advanced to $14.4 million in Q2 2017 per ARGX's latest filing, from $13.2 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $14.4 million in Q2 2017 and bottomed at $13.2 million in Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |